Search results
Results from the WOW.Com Content Network
Ranbaxy competed with the maker of brand-name Zocor, Merck & Co.; IVAX Corporation (which was acquired by and merged into Teva Pharmaceutical Industries Ltd.), which has 180-day exclusivity at strengths other than 80 mg; and Dr. Reddy's Laboratories and India, whose authorized generic version (licensed by Merck) is exempt from exclusivity.
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare ...
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical ...
In comparison, Merck has a contract with the U.S. government to supply 1.7 million courses of the drug at a price of $700 per course. India's Optimus Pharma seeks approval to produce generic Merck ...
Dr. Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new COVID-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer ...
Dow component Merck (NYS: MRK) may be a juggernaut of the pharmaceutical industry, but there are plenty of reasons to be both bullish and bearish on this stock. In our brand new premium research ...
A copy of the Information Statement sent to Merck shareholders was filed with the U.S. SEC on April 20, 2021, in a Form 10-12B/A, Exhibit 99.1 [16] [17] In November 2021, the business announced it would acquire Forendo Pharma and its lead compound, a potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor.
2014 – Merck KGaA announced that it would purchase Sigma-Aldrich for approx. $17 billion (€13.1 billion). [16] [17] November 3, 2014 – Sigma-Aldrich filed a definitive proxy statement with the U.S. Securities and Exchange Commission to hold a special investors meeting regarding approval for the sale to Merck KGaA. [18]